These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30932719)

  • 1. Assessment of potentially abuse-related events in two phase 3 studies of NKTR-181, a novel opioid analgesic, using the MADDERS® system (Misuse, Abuse, and Diversion Drug Event Reporting System).
    Lanier RK; Henningfield JE; Gudin J; Rauck R; Elder H; Erpelding N; Treister R; Gimbel J; Tagliaferri M; Doberstein SK; Di Fonzo CJ; Lu L; Siddhanti S; Katz NP
    Curr Med Res Opin; 2019 Sep; 35(9):1513-1522. PubMed ID: 30932719
    [No Abstract]   [Full Text] [Related]  

  • 2. Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain.
    Henningfield JE; Gudin J; Rauck R; Gimbel J; Tagliaferri M; Doberstein SK; Di Fonzo C; Lu L; Katz N; Siddhanti S; Schnoll S
    Pain Med; 2020 Aug; 21(8):1553-1561. PubMed ID: 32150255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS).
    Gudin J; Rauck R; Argoff C; Agaiby E; Gimbel J; Katz N; Doberstein SK; Tagliaferri M; Tagliaferri M; Potts J; Wild J; Lu L; Siddhanti S; Hale M; Markman J
    Pain Med; 2020 Nov; 21(7):1347-1356. PubMed ID: 31361019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain.
    Markman J; Gudin J; Rauck R; Argoff C; Rowbotham M; Agaiby E; Gimbel J; Katz N; Doberstein SK; Tagliaferri M; Lu L; Siddhanti S; Hale M
    Pain; 2019 Jun; 160(6):1374-1382. PubMed ID: 30747908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.
    Webster L; Henningfield J; Buchhalter AR; Siddhanti S; Lu L; Odinecs A; Di Fonzo CJ; Eldon MA
    Pain Med; 2018 Feb; 19(2):307-318. PubMed ID: 28340145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and feasibility of the misuse, abuse, and diversion drug event reporting system (MADDERS®).
    Treister R; Trudeau JJ; Van Inwegen R; Jones JK; Katz NP
    Am J Addict; 2016 Dec; 25(8):641-651. PubMed ID: 28051840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
    Ge X; Henningfield JE; Siddhanti S; Jobes J; Lu L; Xie S; Ziola M; Kelsh D; Vince B; Di Fonzo CJ; Tagliaferri M; Zalevsky J; Doberstein SK; Hoch U; Eldon MA
    Pain Med; 2020 Feb; 21(2):e114-e126. PubMed ID: 31553457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.
    Smith SM; Jones JK; Katz NP; Roland CL; Setnik B; Trudeau JJ; Wright S; Burke LB; Comer SD; Dart RC; Dionne R; Haddox JD; Jaffe JH; Kopecky EA; Martell BA; Montoya ID; Stanton M; Wasan AD; Turk DC; Dworkin RH
    J Pain; 2017 Nov; 18(11):1287-1294. PubMed ID: 28479207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The opioid crisis: a 21st century pain.
    Walker G
    Drugs Today (Barc); 2018 Apr; 54(4):283-286. PubMed ID: 29869649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential.
    Miyazaki T; Choi IY; Rubas W; Anand NK; Ali C; Evans J; Gursahani H; Hennessy M; Kim G; McWeeney D; Pfeiffer J; Quach P; Gauvin D; Riley TA; Riggs JA; Gogas K; Zalevsky J; Doberstein SK
    J Pharmacol Exp Ther; 2017 Oct; 363(1):104-113. PubMed ID: 28778859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription opioid abuse and misuse: gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic pain.
    Setnik B; Roland CL; Pixton GC; Sommerville KW
    Postgrad Med; 2017 Jan; 129(1):5-11. PubMed ID: 27782769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
    Hale ME; Zimmerman TR; Eyal E; Malamut R
    J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Contribution of Differential Opioid Responsiveness to Identification of Opioid Risk in Chronic Pain Patients.
    Bruehl S; Burns JW; Passik SD; Gupta R; Buvanendran A; Chont M; Schuster E; Orlowska D; France CR
    J Pain; 2015 Jul; 16(7):666-75. PubMed ID: 25892658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1.
    Kaye AD; Jones MR; Kaye AM; Ripoll JG; Galan V; Beakley BD; Calixto F; Bolden JL; Urman RD; Manchikanti L
    Pain Physician; 2017 Feb; 20(2S):S93-S109. PubMed ID: 28226333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    J Opioid Manag; 2015; 11(5):425-34. PubMed ID: 26535970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.